anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit. Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
WELLBUTRIN SR can cause seizure. The risk of seizure is dose-related. The dose should not exceed 400 mg/day. Increase the dose gradually. Discontinue WELLBUTRIN SR and do not restart treatment if the patient experiences a seizure.

The risk of seizures is also related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold. Consider these risks before initiating treatment with WELLBUTRIN SR. WELLBUTRIN SR is contraindicated in patients with a seizure disorder, current or prior diagnosis of anorexia nervosa or bulimia, or undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Contraindications (4), Drug Interactions (7.3)]. The following conditions can also increase the risk of seizure: severe head injury; arteriovenous malformation; CNS tumor or CNS infection; severe stroke; concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids); metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia); use of illicit drugs (e.g., cocaine); or abuse or misuse of prescription drugs such as CNS stimulants. Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin; use of anorectic drugs; and excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates. 

Incidence of Seizure with Bupropion Use

When WELLBUTRIN SR is dosed up to 300 mg/day, the incidence of seizure is approximately 0.1% (1/1,000) and increases to approximately 0.4% (4/1,000) at the maximum recommended dose of 400 mg/day.

The risk of seizure can be reduced if the dose of WELLBUTRIN SR does not exceed 400 mg/day, given as 200 mg twice daily, and the titration rate is gradual.
<P>PROBLEM TO BE SOLVED: To provide a gene carrier having a target-directing property to cells, excellent in transfection ability and being safe.  <P>SOLUTION: A polysaccharide-based gene carrier is composed of a polysaccharide (e.g. β-1,3-glucan) in which side chains are modified with residues of saccharides recognizing cells (e.g. monosaccharide selected from galactose, N-acetylgalactosamine, mannose, N-acetylglucosamine, glucose, fucose and sialic acid and oligosaccharide containing the monosaccharide). A target gene can cell-specifically and efficiently be introduced into a cell by administering the polysaccharide-based carrier as a complex having a triple helical structure and composed of double strands of the polysaccharide gene carrier and a single strand of nucleic acid containing the target gene (e.g. antisense DNA).  <P>COPYRIGHT: (C)2005,JPO&NCIPI
This study will be conducted in the Emergency Department at Stony Brook University Hospital. Investigators intend to enroll approximately 80 patients who present to the emergency department with dyspepsia symptoms. The patients will be randomized to one of two groups: one group will receive 20 mg of intravenous famotidine and the other will receive 30 ml of oral Maalox/ Mylanta. The verbal numeric pain score (VNP) will be used to measure pain at 0 minutes, 15 minutes, 30 minutes, 45 minutes, and 60 minutes after administration of the study drug. Pain severity assessments will be performed by an investigator blinded to study treatment. Data will also be collected regarding demographic, clinical information, patient satisfaction and the need for rescue medications in each of the two study groups at the end of the 60-minute study period. At the end of the study period, the patients may be treated with additional analgesia at the discretion of their ED provider.
The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
IPS Empress CAD is a leucite glass-ceramic of the SiO2-Al2-O3-K2O material systems with leucite crystal ranging from 5 to 10 µm in size. The leucite crystals increase the material strength and interferes with crack propagation, while the fracture energy is absorbed by the crystalline phase. The resistance and flexural strength (160 Mpa) is improved by the difference in the coefficient of thermal expansion between the glass phase and the crystalline phase and the cooling process following sintering phase.

CELTRA DUO: is a new generation of glass ceramic material. With the aid of a new manufacturing process, the glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic (ZLS). The material is characterized by a unique homogenous structure with fine grains that provides excellent material quality and consistency, high strength properties and long term performance. In addition, the material offers satisfying processing characteristics which can be milled and polished easily. After milling the restorations are shaded correctly shaded, with no need for crystallization step 10. The milled restorations have a flexural strength of 210 MPa. After stain and glaze firing the restoration will exhibit a flexural strength up to 370 MPa.
BACKGROUND: Patients with chronic diffuse sclerosing osteomyelitis/tendoperiostitis (DSO/TP) of the mandible may complain about facial asymmetry as a result of mandibular deformity, one of the characteristics of DSO/TP of the mandible. If the disease is fully extinguished, remodelling surgery could be performed to treat complaints of facial asymmetry. This study reports the results of remodelling surgery with three-dimensional (3D) designed- and -printed patient-specific surgical guides.
MATERIAL AND METHODS: 3D printed guides were designed and manufactured by using mirroring of the contralateral non-affected mandible. Subsequently, the surgical procedure was performed under general anaesthesia using these surgical guides.
RESULTS: Four patients (all female) aged 15 (±2.8) years were included. They all complained about facial asymmetry and were planned for surgery with patient-specific surgical guides. Three of those surgeries were performed, of which two patients were satisfied with the result and the other patient is planned for re-surgery because of persistent aesthetical complaints. The last patient cancelled her surgery, because she eventually accepted her asymmetry with the help of a psychologist.
CONCLUSIONS: The use of patient-specific surgical guides in remodelling surgery of the mandible could enable a more predictable and symmetrical outcome, which could minimise the chance for re-surgery and could increase patient satisfaction. Furthermore, it could minimise the chance of iatrogenic damage to the inferior alveolar nerve.
The invention discloses a new product body membrane, which is a close-fitting transparent membrane with the appearance of a human body shape, is made of non-woven fabric fiber fabrics, is divided into a front body whole membrane and a back body whole membrane according to the human body part after being cut, and can be divided into a foot membrane, a leg membrane, a hip membrane, a pleura, an upper body membrane and a back membrane according to each part of the human body. It is combined with essence beneficial to human body to form a brand new application method. It is also a completely new category of skin care products. Is used for moisturizing skin of various parts of body, and also has effects of keeping moisture, moistening, nourishing, improving appearance, and deeply cleaning. Including both gel-containing nonwoven fabric patches and impregnated nonwoven fabric patches. Mechanically cutting the non-woven fabric into the shape of adult body part, placing into a package, and filling essence or coating on the fabric surface, sealing the package, taking out from the package, and sticking on the body.
FIELD: medicine. SUBSTANCE: proposed medicinal agent is prepared on the basis of ecologically pure magnesium-chloride brine mineral bischofite and has, g: brine of magnesium-chloride mineral bischofite with specific density 1,27± 0,01 g/cm 3  100; slastilin 0.01; menthol 0.005; thymol 0.005, and stabilizing agent 0.0002-0.005. Proposed agent shows antiinflammatory effect, accelerates healing infected and noninfected ulcer defects of mucosa in mouth cavity, stimulates phagocytosis and can be used in stomatology. Effectiveness of proposed agent exceeds that of foreign agents. EFFECT: increased effectiveness of agent proposed. 12 tbl
No significant effect of LEVAQUIN® on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that LEVAQUIN® enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and LEVAQUIN® use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if LEVAQUIN® is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [see Adverse Reactions (6.3); Patient Counseling Information (17.4)].
BACKGROUND: Compound chenpi tea (CCT) is a popular herbal beverage made from citri reticulatae pericarpium, Ganoderma lucidum, and pu-erh tea. This study aimed to investigate the anti-obesity effect of CCT in mice fed a high-fat diet (HFD) and to explore the potential mediators by 16S ribosomal RNA sequencing and serum metabolomic analysis.
RESULTS: The results showed that CCT supplementation can effectively reduce diet-induced obesity, hepatic steatosis, dyslipidemia, and insulin resistance. Further analyses revealed that CCT could reverse the changes of 28 metabolites induced by HFD, mainly affecting, amino acid metabolism, gut microbiota metabolism, and glycerophospholipid metabolism. CCT could also alleviate the intestinal dysbiosis by decreasing the abundance of Romboutsia, Gemella, [Eubacterium]_fissicatena_group, and Faecalibaculum, and increasing the abundance of Oscillibacter, Blautia, and Acetatifactor.
CONCLUSION: Collectively, these findings demonstrated that CCT supplementation modulated gut microbiota and obesity-related metabolic disorders in mice. © 2023 Society of Chemical Industry.
PURPOSE: A skin application composition containing conjugated linoleic acid and L-carnitine is provided to ensure excellent fat reduction. CONSTITUTION: A skin application composition for fat reduction contains conjugated linoleic acid and L-carnitine. The conjugated linoleic acid comprises pure CLA and other fatty acid except for pure CLA. The composition contains 0.1-90 weight% of pure CLA. The pure CLA contains c9, t11 CLA and t10, c12 CLA. A method or preparing the composition for fat reduction comprises: a step of preparing a first solution in which L-carnitine is dissolved in ethanol; a step of preparing a second solution by mixing conjugated linoleic acid with the first solution; and a step of decompressing the second solution.
After lung transplantation, many complications related to various reasons are observed in patients in the long term. In this study, the severity of fatigue, limitation of daily living activities, kinesophobia, impaired sleep quality, anxiety and depression level, fragility level, balance and functional capacity in lung transplant recipients; investigators aimed to examine the relationship between the age at which the patient was transplanted and the level of comorbidity. Although there are studies on comorbidities, quality of life, daily living activities and participation level, anxiety and depression level, sleep quality, balance and physical fitness level in lung transplant recipients, kinesiophobia upper extremity functional performance in patients who have undergone lung transplantation surgery, COVID-19 infection There are no studies evaluating the anxiety associated with the disease. No study evaluating body structure functions, activity and participation level based on ICF in lung transplantation has been encountered. In our study, patients with at least 3 months past lung transplantation and without orthopedic and mental problems will be evaluated. It will be made as a single evaluation. The last pulmonary function test results of the patients, comorbidity conditions, fatigue, respiratory quality of life, coronavirus anxiety status, sleep quality, kinesophobia will be evaluated by questionnaires. Lower extremity dynamic balance and mobility will be evaluated with 1 minute sit-to-stand test, timed up and go test. Upper extremity functionality will be evaluated with a 6-minute pegboard and ring test.
A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease. A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents. A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogen used in the contraceptive. The amount of both hormones should be considered in the choice of an oral contraceptive. 

Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular estrogen/progestogen combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest estrogen content which is judged appropriate for the individual patient.
This study will be a single-center, examiner-blind, randomized, stratified, three-treatment, parallel group study in healthy adult volunteers with mild to moderate gingivitis. There will be six visits to the study site: Screening, Baseline, Day 3 and Weeks 1, 2 and 6. Gingivitis will be assessed using a Modified Gingival Index (MGI) and a Bleeding Index (BI). Plaque will be assessed by the Turesky modification of the Quigley Hein (TPI). All evaluable teeth (in relation to the inclusion/ exclusion general dentition criteria) will be assessed.

The dosage regimen of twice daily treatment (morning and evening) for the washout dentifrice and study products will be the same for all participants and is based on widely recommended oral hygiene practice/typical consumer habit. Study participants will be instructed to brush for at least 1 timed minute with their assigned study dentifrice on each brushing occasion. After 6 weeks (Day 42+/-3 days) twice daily treatment, each participant should complete between approximately 84-90 treatment applications. During the washout period for this study (minimum 14 days/ maximum 28 days), eligible participants will use a marketed, regular fluoride toothpaste and toothbrush (as provided).
A randomized, prospective, controlled trial was designed, with the participants (n=18) randomly distributed into two groups. The Control Group (n=8) will be receiving the protocolized classes from the course "Masters in Military Aeronautics: aviator pilot specialist" for 12 weeks, the Intervention Group (n=10) will receive the same course and 2 sessions per week (1h each) of the yoga classes (4). The intensity of the program (Borg rating of perceived exertion scale) will be measured. The operative performance response measurements will be collected at baseline and post-intervention. Participants will complete the following emergency protocols in a flight simulator: (1) take-off engine failure, (2) flight engine failure close to the base, (3) flight engine failure far away from the base, and (4) alternator failure. This intervention protocol was accepted by the Portuguese Airforce to be applied on Airbase 11 in Beja.
CONTEXT: There are several procedures for surgical nodal staging in clinically node-negative (cN0) penile carcinoma.
OBJECTIVE: To evaluate the diagnostic accuracy, perioperative outcomes, and complications of minimally invasive surgical procedures for nodal staging in penile carcinoma.
EVIDENCE ACQUISITION: A systematic review of the Medline, Embase, and Cochrane controlled trials databases and ClinicalTrials.gov was conducted. Published and ongoing studies reporting on the management of cN0 penile cancer were included without any design restriction. Outcomes included the false negative (FN) rate, the number of nodes removed, surgical time, and postoperative complications.
EVIDENCE SYNTHESIS: Forty-one studies were eligible for inclusion. Four studies comparing robot-assisted (RA-VEIL) and video-endoscopic inguinal lymphadenectomy (VEIL) to open inguinal lymph node dissection (ILND) were suitable for meta-analysis. A descriptive synthesis was performed for single-arm studies on modified open ILND, dynamic sentinel node biopsy (DSNB) with and without preoperative inguinal ultrasound (US), and fine-needle aspiration cytology (FNAC). DSNB with US + FNAC had lower FN rates (3.5-22% vs 0-42.9%) and complication rates (Clavien Dindo grade I-II: 1.1-20% vs 2.9-11.9%; grade III-V: 0-6.8% vs 0-9.4%) in comparison to DSNB alone. Favourable results were observed for VEIL/RA-VEIL over open ILND in terms of major complications (2-10.6% vs 6.9-40.6%; odds ratio [OR] 0.18; p < 0.01). Overall, VEIL/RA-VEIL had lower wound-related complication rates (OR 0.14; p < 0.01), including wound infections (OR 0.229; p < 0.01) and skin necrosis (OR 0.16; p < 0.01). The incidence of lymphatic complications varied between 20.6% and 49%.
CONCLUSIONS: Of all the surgical staging options, DSNB with inguinal US + FNAC had the lowest complication rates and high diagnostic accuracy, especially when performed in high-volume centres. If DSNB is not available, favourable results were also found for VEIL/RA-VEIL over open ILND. Lymphatic-related complications were comparable across open and video-endoscopic ILND.
PATIENT SUMMARY: We reviewed studies on different surgical approaches for assessing lymph node involvement in cases with penile cancer. The results show that a technique called dynamic sentinel node biopsy with ultrasound guidance and fine-needle sampling has high diagnostic accuracy and low complication rates. For lymph node dissection in penile cancer cases, a minimally invasive approach may offer favourable postoperative outcomes.
To date, there are no established sleep health education programs for healthcare providers. To address this gap, the investigators previously conducted semi-structured interviews with community-based healthcare providers to improve our knowledge and understanding of healthcare providers' attitudes and beliefs about sleep health, factors that may contribute to poor sleep health, and identify potential sleep health promotion strategies for low income, racial and ethnic minority children and their families. Data from those sessions helped to inform and refine content to develop a sleep health education program for community healthcare providers. The purpose of this protocol it assess the effectiveness of the Bedtime Stories Sleep Health Education Program in Community Healthcare Providers (BTS-HP).

Healthcare providers from participating community healthcare centers will be invited to participate. Once a healthcare provider expresses interest in participating, they will receive a REDCap link to provide their informed consent. The provider will then complete a short demographic questionnaire via REDCap. Once the healthcare provider consents and completes the short questionnaire, they will receive a secure link to the Bedtime Stories Sleep Health Education Program for Healthcare Providers (BTS-HP). The BTS-HP is an online sleep health education program supported by the Boston Children's Hospital Department of Education (CE Courses - BCH Education (childrenshospital.org). The provider will also receive access to an educational webinar on Melatonin. The provider can participate all modules and the webinar in one sitting or overtime. Once the provider completes the online modules, they will immediately receive an email with a REDCap link to complete their post-participation questionnaire.
Site Selection: Climara Pro should be placed on a smooth (fold free), clean, dry area of the skin on the lower abdomen. Climara Pro should not be applied to or near the breasts. The area selected should not be oily (which can impair adherence of the system), damaged, or irritated. The waistline should be avoided, since tight clothing may rub the system off or modify drug delivery. The sites of application must be rotated, with an interval of at least one week allowed between applications to the same site. 

Application of the system: After opening the pouch, remove one side of the protective liner, taking care not to touch the adhesive part of the transdermal delivery system with the fingers. Immediately apply the transdermal delivery system to a smooth (fold free) area of skin on the lower abdomen. Remove the second side of the protective liner and press the system firmly in place with the hand for at least 10 seconds, making sure there is good contact, especially around the edges. 

Care should be taken that the system does not become dislodged during bathing and other activities. If a system should fall off, the same system may be reapplied to another area of the lower abdomen. If necessary, a new transdermal system may be applied, in which case, the original treatment schedule should be continued. Only one system should be worn at any one time during one week dosing interval. 

Once in place, the transdermal system should not be exposed to the sun for prolonged periods of time.
PCT No. PCT/US96/18977 Sec. 371 Date May 27, 1999 Sec. 102(e) Date May 27, 1999 PCT Filed Nov. 27, 1996 PCT Pub. No. WO98/23165 PCT Pub. Date Jun. 4, 1998A method for producing a chewing gum with a controlled release of caffeine, as well as the chewing gum so produced, is obtained by physically modifying caffeine's properties by coating and drying. Caffeine is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated caffeine is then co-dried and particle sized to produce a release-modified caffeine. When incorporated into the chewing gum, these particles are adapted to produce a fast release or a delayed release when the gum is chewed.